Last reviewed · How we verify
Betagan (LEVOBUNOLOL)
Betagan (LEVOBUNOLOL) is a small molecule beta-adrenergic blocker developed by Allergan, targeting the beta-2 adrenergic receptor. It is used to treat ocular hypertension and open-angle glaucoma. Betagan is off-patent, with multiple generic manufacturers available. As a beta-blocker, it works by reducing the production of fluid in the eye, thereby lowering intraocular pressure. Key safety considerations include potential effects on heart rate and blood pressure.
At a glance
| Generic name | LEVOBUNOLOL |
|---|---|
| Sponsor | AbbVie |
| Drug class | beta-Adrenergic Blocker |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1985 |
Approved indications
- Ocular hypertension
- Open-angle glaucoma
Common side effects
- Bradycardia
- Arrhythmia
- Hypotension
- Syncope
- Heart block
- Cerebrovascular accident
- Cerebral ischemia
- Congestive heart failure
- Palpitation
- Cardiac arrest
- Respiratory failure
- Dyspnea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Betagan CI brief — competitive landscape report
- Betagan updates RSS · CI watch RSS
- AbbVie portfolio CI